Skip to main content
Signal8

LIPELLA PHARMACEUTICALS INC. (LIPO)

Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc.

OTC:LIPOHealthcare
$0.0006
CLOSED
Mkt Cap$3K
EV-
Float4.4M
O/S4.62M
VOL43K sh
$ Vol$26
RVOL5.50×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
Lipella Pharmaceuticals Inc. logoOTC:LIPOClosed$0.0006
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 4.40M · Signal8 dilution snapshot · Nov 14, 2025

1.2K
Oct 30 (18d)prev 1.2K▼ 0.1%
1.93
Oct 30 (18d)prev 1.58▲ 22.2%
Borrow (IBKR)

The cost to borrow LIPO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
98.9%
Sep 1 (77d)prev 100.0%▼ 1.1 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

234
Oct 13 (35d)
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20261.2K sh
Oct 15, 20261.2K sh
Sep 30, 20261.2K sh
Sep 15, 20261.2K sh
Aug 31, 20261.1K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Sep 1
Latest sessions
DateReported short
Sep 1, 202698.9%
Aug 11, 2026100.0%
Aug 6, 202699.0%
Jul 17, 202613.0%
3-session median 99.0%mean 70.7%range 13.0–100.0%

130 calendar days requested; 4 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for LIPO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 1,192 LIPO shares were sold short (0.03% of a 4.40M-share float, 1.93 days to cover).